PostEra vs Abbott Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.
About
PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.
Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.
About
Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.